This article is more than 5 years old. Information may no longer be current.

Oral CAI adds to effect of topical CAI in pediatric glaucoma, study finds

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Adding an oral carbonic anhydrase inhibitor to the medical regimen in children being treated with a topical CAI for glaucoma may provide additional IOP-lowering effect, a study in Canada found.

Kourosh Sabri, MD, ChB, FRCOphth, and Alex V. Levin, MD, MHSc, FRCSC, of the Hospital for Sick Children in Toronto, reviewed outcomes for 22 glaucoma patients aged younger than 16 years who were treated with both medication types. All children initially used topical dorzolamide and were later given daily oral acetazolamide for a mean duration of 18 days.

Before adding oral acetazolamide, IOP in the patients averaged 32.2 ± 6.5 mm Hg. The researchers found that IOP decreased by a mean 29.6% to 21.8 ± 6.3 mm Hg (P < .0001) at the first examination after initiation of oral acetazolamide treatment.

The additive effect of oral CAI to topical CAI has not been observed in adults, the study authors said.

The study is published in the October issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus.